DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE
Pre-Launchdolutegravir; lamivudine; tenofovir alafenamide
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE (dolutegravir; lamivudine; tenofovir alafenamide) by Inpharmus is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 4w ago
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on DOLUTEGRAVIR;LAMIVUDINE;TENOFOVIR ALAFENAMIDE at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.